An observational study in Glaucoma, sponsored by Marc Toeteberg-Harms. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Marc Toeteberg-Harms · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 3rd largest by planned enrollment of the 110 observational ones that give a count, is one of 21 that started in 2024, is one of 110 observational ones, reaches primary completion later than 25 of the 93 other live ones, and was the 433rd registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Tavo Biotherapeutics · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 21 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 358 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Marc Toeteberg-Harms as lead sponsor.
Marc Toeteberg-Harms has 1 study filed under Glaucoma — fewer than ten, so there is no comparison to draw.
34 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.
any patient with a diagnosis of glaucoma treated or evaluated for glaucoma at the Dept. of Ophthalmology \& Visual Sciences, University of Iowa, Iowa City, IA, USA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
subjects with a diagnosis of glaucoma
Other: GQL-15 · Other: Glaucoma Symptom Scale · Other: NEI Vision Function Questionnaire · Other: Ocular Surface Disease Index
GQL-15 questionnaire
GSS questionnaire
Vision function questionnaire
OSDI questionnaire
Ocular Surface Disease Index (OSDI)
The OSDI© is assessed on a scale of 0 to 4, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function.
Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
Glaucoma Symptom Scale (GSS)
The Glaucoma Symptom Scale (GSS; Lee et al., 1998) was developed as a brief symptom survey specific for persons with glaucoma. The GSS consists of a 10-item scale developed from a modified version of a symptom checklist that address ocular complaints, some of a nonvisual nature and some of a visual nature, common to patients with glaucoma. Items are scored from 0 to 100, where 100 represents the absence of symptoms and 0 represents severe, bothersome symptoms.
Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
National Eye Institute Visual Function Questionaire (NEI VFQ)
Vision-specific instrument designed to measure vision-related quality of life (VRQoL) in adults, incorporating body, activity, and participation content according to the WHO ICF Framework in order to measure the effects of a variety of ocular conditions on daily functioning and QOL. It was originally designed as a 51-point questionnaire and is currently available in both self-administered and interview-based formats. The raw scores are converted to a 0-100 scale; after reverse scoring, a high score (100) indicates better vision-specific quality of life, while a low score (0) indicates poor function.
Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
Glaucoma Quality of Life-15 (GQL-15)
The Glaucoma Quality of Life-15 (GQL-15) is a validated 15-item, self-report questionnaire used to measure visual disability and quality of life (QoL) in glaucoma patients. It covers four key areas-peripheral vision, central/near vision, glare/dark adaptation, and outdoor mobility-using a 5-point scale (1=no difficulty to 5=severe difficulty).
Time frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
Plan to share: Undecided — data will be stored anonymously without patient identifier. It can be shared on a case by case decision.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.
Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 23 months is below that.
Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.